Metagenics is to market Swiss chemical firm Lonza's stomach health supplement PepZin GI to healthcare professionals in the US and Europe.
To be sold under the name Zinlori 75, the patented dietary supplement contains a chelated complex of L-carnosine and zinc.This is the second of several supply channel agreements in to bring PepZin GI to Europe and North America, said Lonza.
PepZin GI has been studied extensively for its ability to interact with Helicobacter pylori, support gastric health, and relieve dyspeptic symptoms.
In Japan, PepZin GI has been sold for over a decade under the name Polaprezinc which is manufactured by Hamari Chemicals. PepZin GI offers exceptional, 'drug-like' patent protection, in that the molecule itself is claimed. This allows Lonza's strategic marketing partners unparalleled exclusivity.
Dan Murray, associate director of technical development for nutrition at Lonza, said: "We are very excited to have Metagenics' pharma-caliber field representatives disseminate the evidence and IP package on PepZin GI and foster adoption within the integrative healthcare sector."